TrialInternational journal of cancer2016

A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy.

Cathy Eng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.